Press kit
Boilerplate
Drug Landscape (druglandscape.com) is an AI-native pharma intelligence platform replacing legacy patent + competitive-intel tools like Clarivate Cortellis and IPlytics with grounded, citable, transparent data. It tracks 16,724 Orange Book patents, 470 BLA biologics, and the patent estates of every public pharma company — with daily refresh, free SEO surface, and Pro-tier AI tools (Freedom-to-Operate scanner, claim analyzer, landscape reports). Based in London, founded 2026.
By the numbers (May 2026)
- 16,724 enriched Orange Book patents with LLM summaries + USPTO grounding + 0-100 vulnerability scoring
- ~3,500 international family members (EP, JP, CN, CA, AU, GB)
- 470 BLA biologics with BPCIA 12-year exclusivity calendars
- 188 drug-level + 72 company-level AI strategic briefs (Eli Lilly, Pfizer, Merck, AbbVie, etc.)
- Daily Pharma IP Brief — emailed at 07:00 UTC, archived at /briefs
- Pricing: Free £0 · Pro £199/mo · Team £499/mo · Enterprise custom
Quotes (for direct use)
"Pharma IP teams have been burned by black-box indices from incumbents. Drug Landscape publishes every parameter in its vulnerability score and validates against real PTAB IPR outcomes — patents we score ≥70 are invalidated at ~4.8× the rate of those scored 0-24." — Drug Landscape
"We replace a tab-stack of Clarivate Cortellis, IPlytics, PatSnap, and stitched-together Excel decks — at 20% of the cost, with AI on every surface." — Drug Landscape
Press contact
Email: hello@druglandscape.com. Available for interviews on pharma patent intelligence, AI in regulated industries, and biosimilar / generic strategy. Based in London.
Story angles we can support
- The patent cliff that's coming. ~$200B of branded revenue exposed to expiry 2025-2030. We can pull custom by-company / by-class data.
- Why Cortellis is losing the IP intelligence market. Black-box scoring, $80k/seat, no AI. Drug Landscape is the disruption story.
- The biosimilar opportunity scan. Which BLA biologics open in 2027-2030 and how concentrated the targets are.
- AI grounding vs hallucination. How we make LLMs reliable for legal-adjacent pharma use cases.
- The UK pharma AI startup wave. Drug Landscape is one of several London-based AI-native challengers to US incumbents.
Reports + data
We grant analysts complimentary Pro access on request. Custom data pulls available for stories — typical turnaround 24-48h.
- Biosimilar Opportunity Scanner — every BLA biologic ranked
- Company Patent Rankings — every pharma co ranked 4 ways
- Daily Pharma IP Brief archive
Logo + screenshots
Logo + product screenshots available on request — email hello@druglandscape.com. PNG + SVG, light + dark.